Page 157 - ADULT-ONSET ASTHMA PREDICTORS OF CLINICAL COURSE AND SEVERITY

PREDICTORS OF FREQUENT EXACERBATIONS IN (EX)SMOKING AND NEVER SMOKING ADULTS WITH SEVERE ASTHMA
REFERENCES
1. (GINA) GINA. Global Strategy for Asthma Management and Preven on 2014 (update). 2014; h p://www. ginasthma.org/local/uploads/ les/GINA_Pocket_2014_Jun11.pdf.
2. Pavord ID. Eosinophilic phenotypes of airway disease. Ann Am Thorac Soc. 2013;10 Suppl:S143-149.
3. Pizzichini MM, Pizzichini E, Clelland L, et al. Prednisone-dependent asthma: in ammatory indices in
induced sputum. The European respiratory journal. 1999;13(1):15-21.
4. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir
Crit Care Med. 2000;161(1):64-72.
5. Green RH, Brightling CE, McKenna S, et al. Asthma exacerba ons and sputum eosinophil counts: a
randomised controlled trial. Lancet. 2002;360(9347):1715-1721.
6. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell
counts: e ect on exacerba ons. The European respiratory journal. 2006;27(3):483-494.
7. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a mul centre,
double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651-659.
8. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocor coid-sparing e ect of mepolizumab in eosinophilic
asthma. N Engl J Med. 2014;371(13):1189-1197.
9. Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. The European respiratory journal.
2013;41(3):716-726.
10. Amelink M, de Nijs SB, de Groot JC, et al. Three phenotypes of adult-onset asthma. Allergy. 2013;68(5):674-680.
11. Westerhof GA, Vollema EM, Weersink EJ, Reinartz SM, de Nijs SB, Bel EH. Predictors for the development of progressive severity in new-onset adult asthma. The Journal of allergy and clinical immunology. 2014.
12. de Groot JC, van Roon EN, Storm H, et al. Vitamin D reduces eosinophilic airway in amma on in nonatopic asthma. The Journal of allergy and clinical immunology. 2015;135(3):670-675 e673.
13. Chung KF, Wenzel SE, Brozek JL, et al. Interna onal ERS/ATS guidelines on de ni on, evalua on and treatment of severe asthma. The European respiratory journal. 2014;43(2):343-373.
14. ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerba ons in di cult-to-treat asthma. The European respiratory journal. 2005;26(5):812-818.
15. Kupczyk M, ten Brinke A, Sterk PJ, et al. Frequent exacerbators--a dis nct phenotype of severe asthma. Clin Exp Allergy. 2014;44(2):212-221.
16. Juniper EF, O’Byrne PM, Guya GH, Ferrie PJ, King DR. Development and valida on of a ques onnaire to measure asthma control. European Respiratory Journal. 1999;14(4):902-907.
17. Juniper EF, Guya GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evalua on of Impairment of Health Related Quality-Of-Life in Asthma - Development of A Ques onnaire for Use in Clinical-Trials. Thorax. 1992;47(2):76-83.
18. Miller MR, Hankinson J, Brusasco V, et al. Standardisa on of spirometry. European Respiratory Journal. 2005;26(2):319-338.
19. MacIntyre N, Crapo RO, Viegi G, et al. Standardisa on of the single-breath determina on of carbon monoxide uptake in the lung. European Respiratory Journal. 2005;26(4):720-735.
20. Wanger J, Clausen JL, Coates A, et al. Standardisa on of the measurement of lung volumes. European Respiratory Journal. 2005;26(3):511-522.
21. Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway Responsiveness - Standardized Challenge Tes ng with Pharmacological, Physical and Sensi zing S muli in Adults - Report Working Party Standardiza on of
155